Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;98(16):e15282.
doi: 10.1097/MD.0000000000015282.

Liuwei Dihuang Decoction for primary osteoporosis: A protocol for a systematic review and meta-analysis

Yu Liu  1 , Ping Wang  2 , Xiuqun Shi  3 , Huijin Li  1 , Xionghui Zhang  1 , Shenghu Zeng  1 , Zhoufa Xu  1 , Dongqing Lai  1 , Minling Zhang  1
Affiliations

Liuwei Dihuang Decoction for primary osteoporosis: A protocol for a systematic review and meta-analysis

Yu Liu et al. Medicine (Baltimore). 2019 Apr.

Abstract

Background: Primary osteoporosis (POP) is one kind of global disease, as a serious threat to human health. Liuwei Dihuang Decoction (LWDHD) has been recommended to treat osteoporosis alone or combined with medicine in China; however, its efficacy is unclear. The object of this systematic review and meta-analysis is to evaluate the efficacy and safety of LWDHD in the management of POP.

Methods: We will search The Cochrane Library, Medline, PubMed, Elsevier, Springer, Web of Science, Ovid, WHO ICTRP, CNKI, CBM, VIP, and WanFang Database from their inception to February 2019. All randomized controlled trials (RCTs) of LWDHD for the treatment of POP will be included. The language is limited to Chinese and English. The fracture incidence will be accepted as the primary outcomes. Data synthesis, subgroup analysis, sensitivity analysis will be performed by using RevMan V.5.3.5 software.

Results: A high-quality synthesis of current evidence for the treatment of POP with LWDHD will be provided from efficacy and safety.

Conclusion: This systematic review will generate evidence for judging whether LWDHD is an effective and safe intervention for POP or not.

Prospero registration number: PROSPERO CRD 4201926066.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) flowchart.
See this image and copyright information in PMC

References

    1. Caillet P. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Osteoporos Int 1987;295:914–5. - PMC - PubMed
    1. Lu Y, Genant HK, Shepherd J, et al. Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 2001;16:901–10. - PubMed
    1. Parfitt AM. Primary osteoporosis. Lancet 1980;1:773–4. - PubMed
    1. Czerwiński E, Badurski JE, Marcinowskasuchowierska E, et al. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 2007;9:337–56. - PubMed
    1. Lin X, Xiong D, Peng YQ, et al. Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives. Clin Interv Aging 2015;10:1017–33. - PMC - PubMed

MeSH terms

Substances